Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M800Revenue $M17.3Net Margin (%)-207.9Z-Score4.1
Enterprise Value $M703EPS $-0.6Operating Margin %-197.3F-Score4
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-207.9Higher ROA y-yN
Price/Book9.610-y EBITDA Growth Rate %-7.6Quick Ratio2.7Cash flow > EarningsY
Price/Sales35.95-y EBITDA Growth Rate %7.3Current Ratio2.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-45.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-114.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M71.9ROI % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRXGeorge Soros 2014-06-30 Sold Out -0.01%$7.37 - $12.52
($9.68)
$ 11.1315%Sold Out0
BCRXGeorge Soros 2014-03-31 Buy 0.01%$7.6 - $12.83
($10.56)
$ 11.135%New holding, 59700 sh.59,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STAAB THOMAS R IISenior Vice President and CFO 2014-08-27Sell10,000$13.58-18.04view
STAAB THOMAS R IISenior Vice President and CFO 2014-07-01Sell3,125$13-14.38view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-23Sell3,125$12.49-10.89view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-17Sell3,125$12-7.25view
STAAB THOMAS R IISenior Vice President and CFO 2014-03-14Sell3,125$11.24-0.98view
LEE KENNETH B JRDirector 2014-03-06Sell12,665$12.69-12.29view
STAAB THOMAS R IISenior Vice President and CFO 2014-03-04Sell3,000$12.69-12.29view
Babu Yarlagadda SSenior VP - Drug Discovery 2014-03-04Sell40,642$12.57-11.46view
Barnes Alane PVP, General Counsel & Corp Sec 2014-03-04Sell40,734$12.63-11.88view
ABERCROMBIE GEORGE BDirector 2013-11-12Buy3,000$6.1979.81view

Press Releases about BCRX :

    Quarterly/Annual Reports about BCRX:

    News about BCRX:

    Articles On GuruFocus.com
    comment on BCRX Mar 02 2013 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

    More From Other Websites
    From penny-stock fears to first-of-kind flu treatment: The story of Rapivab Dec 22 2014
    FDA approves BioCryst's intravenous flu drug Dec 22 2014
    BioCryst gets FDA approval for flu drug Rapivab Dec 22 2014
    BioCryst gets FDA approval for flu drug Rapivab Dec 22 2014
    BioCryst says FDA approves oral flu drug Rapivab Dec 22 2014
    BioCryst says FDA approves oral flu drug Rapivab Dec 22 2014
    AbbVie gets boost from Express Scripts; American Apparel confirms a suitor; Sony may release 'The... Dec 22 2014
    Stocks extend last week's rally; Express Scripts picks AbbVie drug; Sony attorney says 'The... Dec 22 2014
    6:11 am BioCryst Pharm receives FDA approval for the treatment of acute uncomplicated influenza Dec 22 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2014
    FDA approves BioCryst's flu shot Dec 22 2014
    BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute... Dec 22 2014
    BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute... Dec 22 2014
    BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema Dec 18 2014
    BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema Dec 18 2014
    BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of... Dec 15 2014
    It Could be a Big December for Biotech ETFs Dec 04 2014
    BioCryst to Present at Two Upcoming Investor Conferences Nov 20 2014
    BioCryst to Present at Two Upcoming Investor Conferences Nov 20 2014
    BIOCRYST PHARMACEUTICALS INC Financials Nov 14 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK